GlassScriptPhysician profile
Rachel E Perkins
NPI 1750924676
$7,828.26
in general payments reported to CMS, 2019-2025
27 companies · $2,331 in 2025
The $2,331 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $1,655 · 2023: $1,518 · 2024: $1,990 · 2025: $2,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,334 · Education: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,333.73 |
| Education | $505.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,413.09 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,365.54 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $806.24 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $608.05 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $465.59 | 2021-2024 | Ilumya, Blu-U, Odomzo |
| Amgen INC. | $416.91 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $399.24 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $346.56 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $342.47 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $304.43 | 2024-2025 | |
| Galderma Laboratories, L.P. | $273.70 | 2022-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $263.35 | 2021-2025 | Adbry |
| Pfizer INC. | $215.72 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $119.25 | 2021-2025 | Acthar |
| Arcutis Biotherapeutics, INC. | $115.29 | 2023-2024 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $79.10 | 2021-2024 | Opzelura |
| Biofrontera INC. | $37.69 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.42 | 2022-2023 | Spevigo |
| Pacira Therapeutics, INC. | $36.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.06 | 2021-2025 | Tremfya |
| Verrica Pharmaceuticals INC. | $29.70 | 2024 | Ycanth |
| Avita Medical Americas, LLC | $27.61 | 2024 | |
| Dermavant Sciences, INC. | $27.30 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.33 | 2022 | |
| Epi Health, LLC | $19.61 | 2022 | |
| Ani Pharmaceuticals, INC. | $13.94 | 2025 | Purified Cortrophin Gel |
| Organon LLC | $9.91 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.